Fiche centre
Hopital Gui de Chauliac; Neurologie
Montpellier — France
Essais liés3clinical trials
VilleMontpellierlocalisation
PaysFrancelocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT02861014
Essais cliniques associés
3| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Ocrelizumab | SEP | Phase 3 | NCT02861014 | A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) | COMPLETED |
| Ocrelizumab 300 mg | SEP | Phase 4 | NCT03589105 | PRO-MSACTIVE — A Study to Provide Complementary Efficacy, Safety and Patient Reported Outcomes Data in Participants With Active Relapsing Forms of Multiple Sclerosis (MS) in a Pragmatic Setting | COMPLETED |
| Ocrelizumab | SEP | Phase 3 | NCT01194570 | ORATORIO — A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis | COMPLETED |